| GWW |
Report |
Net sales |
BEAT |
pred ~$4.98B vs. cons $4.90B |
MEDIUM |
| GWW |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$11.55 vs. cons $11.30 |
MEDIUM |
| GWW |
Report |
Operating margin |
IN-LINE |
pred ~15.1% vs. cons 15.2% |
MEDIUM |
| GWW |
Guide |
FY2026 net-sales guidance |
UNCHANGED |
guide ~$19.40B vs. cons $19.43B (FY2026) |
MEDIUM |
| GWW |
Guide |
FY2026 adjusted diluted EPS guidance |
LOWER |
guide ~$45.25 vs. cons $45.60 (FY2026) |
MEDIUM |
| GWW |
Guide |
FY2026 operating-margin guidance |
UNCHANGED |
guide ~15.8% vs. cons 15.8% (FY2026) |
MEDIUM |
| GWW |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.4% |
— |
MEDIUM |
| GWW |
Return |
5-day cumulative residual |
+0.3% (FADE) |
A ~$11.55 EPS result versus $11.30 consensus and ~$4.98B revenue versus $4.90B should support an initial +1.4% residual move, but a ~$45.25 FY2026 EPS midpoint versus $45.60 consensus leaves modest out-period downside despite the quarterly beat, limiting estimate-revision support and producing a fade to +0.3% by day five. |
MEDIUM |